New combo therapy aims to control advanced breast cancer
NCT ID NCT06726148
First seen Jun 27, 2026 · Last updated Jul 14, 2026 · Updated 2 times
Summary
This study tests a new drug called ECI830, alone or with other cancer drugs (ribociclib and fulvestrant), in people with advanced hormone receptor-positive, HER2-negative breast cancer or certain solid tumors. The goal is to find safe doses and see if the combination can slow cancer growth. About 280 adults will take part across multiple centers.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED CCNE1-AMPLIFIED SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Dana Farber Cancer Institute
RECRUITINGBoston, Massachusetts, 02115, United States
-
Florida Cancer Specialists
RECRUITINGFort Myers, Florida, 33901, United States
-
Fred Hutch Cancer Research
RECRUITINGSeattle, Washington, 98109, United States
-
MD Anderson Cancer Center Uni of Te
RECRUITINGHouston, Texas, 77030, United States
-
Memorial Sloan Kettering
RECRUITINGNew York, New York, 10017, United States
-
Novartis Investigative Site
RECRUITINGClayton, Victoria, 3168, Australia
-
Novartis Investigative Site
RECRUITINGMelbourne, Victoria, 3004, Australia
-
Novartis Investigative Site
RECRUITINGToronto, Ontario, M5G 2M9, Canada
-
Novartis Investigative Site
RECRUITINGMontreal, Quebec, H4A 3J1, Canada
-
Novartis Investigative Site
RECRUITINGNanjing, Jiangsu, 210029, China
-
Novartis Investigative Site
RECRUITINGXian, Shanxi, 710061, China
-
Novartis Investigative Site
RECRUITINGBrno, 656 53, Czechia
-
Novartis Investigative Site
RECRUITINGCopenhagen, DK-2100, Denmark
-
Novartis Investigative Site
RECRUITINGOdense C, 5000, Denmark
-
Novartis Investigative Site
RECRUITINGBordeaux, 33076, France
-
Novartis Investigative Site
RECRUITINGSaint-Herblain, 44805, France
-
Novartis Investigative Site
RECRUITINGFreiburg im Breisgau, Baden-Wurttemberg, 79106, Germany
-
Novartis Investigative Site
RECRUITINGHeidelberg, 69120, Germany
-
Novartis Investigative Site
RECRUITINGUlm, 89081, Germany
-
Novartis Investigative Site
RECRUITINGHaifa, 3109601, Israel
-
Novartis Investigative Site
RECRUITINGTel Aviv, 6423906, Israel
-
Novartis Investigative Site
RECRUITINGModena, MO, 41124, Italy
-
Novartis Investigative Site
RECRUITINGMilan, 20141, Italy
-
Novartis Investigative Site
RECRUITINGChuo Ku, Tokyo, 1040045, Japan
-
Novartis Investigative Site
RECRUITINGSingapore, 119074, Singapore
-
Novartis Investigative Site
RECRUITINGSeoul, Seoul, 03080, South Korea
-
Novartis Investigative Site
RECRUITINGBarcelona, 08035, Spain
-
Novartis Investigative Site
RECRUITINGBarcelona, 08036, Spain
-
Novartis Investigative Site
RECRUITINGTainan, 704, Taiwan
-
Novartis Investigative Site
RECRUITINGLondon, Oxford, OX3 7LE, United Kingdom
-
SCRI Oncology Partners
RECRUITINGNashville, Tennessee, 37203, United States
-
University of California LA
RECRUITINGLos Angeles, California, 90095, United States
-
WA Uni School Of Med
RECRUITINGSt Louis, Missouri, 63110, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Two-Drug attack shrink tough lung cancers?
- Can a smartphone app ease the burden of advanced lung cancer?
- New pill targets cancer growth at the genetic level
- Blood test timing could unlock secrets of advanced breast cancer
- Cholesterol-Lowering drug may boost lung cancer immunotherapy
- Lung cancer drug tislelizumab under Real-World scrutiny in 440-Patient european study